bioMerieux offers two ranges of rapid tests to provide quick answers to urgent clinicians needs. Our VIKIA range is mainly designed to meet the needs of global health organizations, while the BIONEXIA range is worked out to meet laboratory needs.
bioMérieux is a recognized leader in in vitro diagnostics with over 50 years of experience and expertise. Our company is committed to improving global health, including fighting infectious diseases and viruses, and identifying markers that signal a health-related change in the body.
The First Line Biology™ solution translates bioMérieux's commitment for rapid diagnostic tests (RDT), a concentrate of the company's know-how in workflow and good practices and its ability to meet the highest quality standards.
The First Line Biology™ solution addresses a specific part of the diagnostic process, taking into account its needs: urgency, reliability and quality.
The VIKIA® and BIONEXIA® product ranges provide a reliable first answer in the diagnostic process, helping healthcare professionals to improve their workflow and optimize their budget, their time and their patients' time. As a logical extension to the company’s offer, the First Line Biology™ solution represents bioMérieux's commitment to meet the needs of global health organizations and labs for more complete rapid test solutions.
The First Line Biology™ products follow the same quality policy as all other bioMérieux products: they meet all quality processes and standards. Quality control is stringent from suppliers to raw materials to fabrication to stock. Both external and internal audits take place to ensure standards are being met. The First Line Biology™ signature guarantees bioMérieux quality inside.
A dedicated R&D team and a dedicated production site help to ensure high-quality products and reliable supply.
Because rapid diagnostic tests can play a decisive role in optimizing prevention and improving patient care in global health, the VIKIA® brand is mainly designed to meet the needs of global health organizations.
VIKIA® provides accurate results for HIV, Malaria and Hepatitis:
|VIKIA® HIV 1/2||3rd generation HIV-1 / HIV-2 kit in whole blood, serum and plasma|
|VIKIA® HBs Ag||Detection of hepatitis B surface antigen in whole blood, serum and plasma|
|VIKIA® Malaria Ag Pf/Pan||Combo assay for the qualitative detection of malaria infections in whole blood|
|VIKIA® anti-HCV||Rapid Hepatitis C screening in all settings|
The First Line Biology™ signature guarantees the quality for the VIKIA® and BIONEXIA® Range.
Labs are increasingly concerned with being able to respond quickly and reliably to patients' and clinicians' demands. The BIONEXIA® range of rapid tests offers a complete solution for the first diagnostic answer.
|BIONEXIA® H. pylori Ag||Cost-effective and non-invasive detection of H. pylori antigen in stool samples|
|BIONEXIA® Legionella||Rapid detection of Legionella pneumophila serogroup 1 in urine|
|BIONEXIA® Strep A plus and BIONEXIA® Strep A dipstick||Detection of Group A Streptococcus infections in throat swabs|
|BIONEXIA® Influenza A+B||Detection and differentiation of Influenza A and B viruses in nasopharyngeal specimens|
|BIONEXIA ® FOBplus||Detection in stools of human hemoglobin potentially linked to colorectal cancer|
|BIONEXIA® hCG Urine and BIONEXIA® hCG Combo||Detection of Human Chorionic Gonadotrophin (hCG) in urines and human serum / an aid in the early detection of pregnancy|
|BIONEXIA® BTA||Screening of bladder cancer|
|BIONEXIA® Rota-Adeno||Aid for rapid, differential diagnosis of viral gastroenteritis|
|BIONEXIA® Noro/Rota-Adeno||Rapid 3-in-1 detection of main gastroenteritis viruses|
Please consult your local bioMérieux representative for product availability in your country